Clinical trial
Phase IB Trial of Niraparib and Dostarlimab (TSR-042) in Patients With BRCA-Mutated Breast, Pancreas or Ovary Cancer
NCT04673448 is registered in ClinicalTrials.gov with University of Washington as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase IB Trial of Niraparib and Dostarlimab (TSR-042) in Patients With BRCA-Mutated Breast, Pancreas or Ovary Cancer
- Lead sponsor
- University of Washington
- Phase
- Phase 1
- Overall status
- Active, not recruiting
- Start date
- October 18, 2021
- Completion date
- September 30, 2027
- Enrollment
- 18 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
anatomic stage iii breast cancer ajcc v8, anatomic stage iv breast cancer ajcc v8, brca hereditary ovarian carcinoma, brca-associated malignant neoplasm, metastatic brca hereditary breast carcinoma, metastatic breast carcinoma, metastatic fallopian tube carcinoma, metastatic malignant solid neoplasm, metastatic ovarian carcinoma, metastatic pancreatic carcinoma, metastatic primary peritoneal carcinoma, prognostic stage iii breast cancer ajcc v8, prognostic stage iv breast cancer ajcc v8, stage iii fallopian tube cancer ajcc v8, stage iii ovarian cancer ajcc v8, stage iii pancreatic cancer ajcc v8, stage iii primary peritoneal cancer ajcc v8, stage iv fallopian tube cancer ajcc v8, stage iv ovarian cancer ajcc v8, stage iv pancreatic cancer ajcc v8, stage iv primary peritoneal cancer ajcc v8, unresectable breast carcinoma, unresectable fallopian tube carcinoma, unresectable malignant solid neoplasm, unresectable ovarian carcinoma, unresectable pancreatic carcinoma, unresectable primary peritoneal carcinoma